Ország: Egyesült Királyság
Nyelv: angol
Forrás: MHRA (Medicines & Healthcare Products Regulatory Agency)
Rosuvastatin calcium
Milpharm Ltd
C10AA07
Rosuvastatin calcium
10mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02120000; GTIN: 8901175028689
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again • If you have any further questions, ask your doctor or pharmacist • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Rosuvastatin is and what it is used for 2. What you need to know before you take Rosuvastatin 3. How to take Rosuvastatin 4. Possible side effects 5. How to store Rosuvastatin 6. Contents of the pack and other information Rosuvastatin belongs to a group of medicines called statins. YOU HAVE BEEN PRESCRIBED ROSUVASTATIN BECAUSE: • You have a HIGH CHOLESTEROL LEVEL. This means you are AT RISK FROM A HEART ATTACK OR STROKE. Rosuvastatin is used in adults, adolescents and children 6 years or older to treat high cholesterol. You have been advised to take a statin, because changing your diet and taking more exercise were not enough to correct your cholesterol levels. You should continue with your cholesterol-lowering diet and exercise while you are taking Rosuvastatin. WHY IS IT IMPORTANT TO KEEP TAKING ROSUVASTATIN? Rosuvastatin is used to correct the levels of fatty substances in the blood called lipids, the most common of which is cholesterol. There are different types of cholesterol found in the blood – 'bad' cholesterol (LDL-C) and 'good' cholesterol (HDL- C). • Rosuvastatin can reduce the 'bad' cholesterol and increase the 'good' cholesterol. • It works by helping to block your body's production of 'bad' cholesterol. It also improves your body's ability to remove it from your blood. For most people, high cholesterol does not affect the way they feel because it does not produce any symptoms. However, if it is left untreated, fatty depo Olvassa el a teljes dokumentumot
OBJECT 1 ROSUVASTATIN 10MG FILM-COATED TABLETS Summary of Product Characteristics Updated 05-Jan-2018 | Aurobindo Pharma - Milpharm Ltd. 1. Name of the medicinal product Rosuvastatin 10 mg film-coated tablets 2. Qualitative and quantitative composition Each film-coated tablet contains 10 mg of Rosuvastatin (as rosuvastatin calcium). Excipient with known effect: Each 10 mg tablet contains 45.878 mg lactose monohydrate, 0.015 mg allura red AC and 0.013 mg Sunset yellow FCF. For the full list of excipients, see section 6.1. 3. Pharmaceutical form Film-coated tablet. Pink coloured, round shaped [diameter 5.8 mm], biconvex film-coated tablets, debossed with 'J' on one side and '54' on the other side. 4. Clinical particulars 4.1 Therapeutic indications TREATMENT OF HYPERCHOLESTEROLAEMIA Adults, adolescents and children aged 6 years or older with primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate. Homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate. 4.2 Posology and method of administration Before treatment initiation the patient should be placed on a standard cholesterol-lowering diet that should continue during treatment. The dose should be individualised according to the goal of therapy and patient response, using current consensus guidelines. Rosuvastatin may be given at any time of day, with or without food. TREATMENT OF HYPERCHOLESTEROLAEMIA The recommended start dose is 5 or 10 mg orally once daily in both statin naïve or patients switched from another HMG CoA reductase inhibitor. The choice of start dose should take into account the individual patient's cholesterol level and future cardiovascular risk as well as the potential risk for adverse reactions (see below). A dose adjustment to the next Olvassa el a teljes dokumentumot